abcentra

Abcentra is a clinical-stage biopharmaceutical company developing first-in-class treatments for cardiovascular and inflammatory diseases. The company’s pipeline focuses on treating patient populations with significant residual risk of accelerated atherosclerosis, cardiovascular events, and valvular disease due to chronic inflammation. Abcentra is developing a therapeutic solution for patients with residual cardiovascular event risk driven by inflammation. The therapeutic goal is to block oxidized low-density lipoprotein (LDL), with research efforts directed toward developing bovine LDL-blocking therapies for patients at significant residual risk of major cardiovascular events caused by chronic inflammation (pipeline). The lead candidate, orticumab, is a fully human, first-in-class antibody targeting a specific oxidized LDL epitope.